Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
valsartan + metformin
- Development stage
- Phase 4
- Lead developer
- Myopharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Valsartan + metformin is a combination drug therapy that pairs an angiotensin receptor blocker (valsartan) with a biguanide antidiabetic medication (metformin). This combination is being studied for use in patients with both type 2 diabetes and hypertension. Valsartan works by blocking angiotensin II receptors, which helps lower blood pressure, while metformin improves insulin sensitivity and reduces glucose production in the liver. Studies suggest this combination may have synergistic effects, with valsartan potentially enhancing the hypoglycemic effects of metformin.
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)AGTR1 (Angiotensin II Type-1 receptor)ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on valsartan + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on valsartan + metformin.